Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
Skye Bioscience selects NextPharma as phase 2 contract drug manufacturer
07:50am, Thursday, 21'st Jul 2022
Skye Bioscience Inc (OTCQB:SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, said it has selected NextPharma as its contract manufacturing o
Skye Bioscience reports slight delay in the production of its Phase 1 drug to treat glaucoma
07:44am, Wednesday, 20'th Jul 2022
Skye Bioscience inc (OTCQB:SKYE) said completion of the production of its Phase 1 drug has been delayed to the beginning of September 2022 due to a now resolved cyber-attack and planned maintenance s
Skye Bioscience gets regulatory approval for first-in-human Phase 1 clinical study of patented drug as potential treatment for glaucoma
08:28am, Thursday, 30'th Jun 2022
Skye Bioscience inc (OTCQB:SKYE) has received regulatory approval to begin its first-in-human Phase 1 clinical study of SBI-100 Ophthalmic Emulsion, a patented drug representing a new class of therape
Skye Bioscience is primed for meaningful clinical development of cannabinoid-derivative drug SBI-100 OE for glaucoma
07:01am, Tuesday, 28'th Jun 2022
Small companies accessing capital to fund growth mostly have an uphill challenge. With inflation slamming the global economy like a wrecking ball this year, the market mayhem is going to make it even
Skye Bioscience enters research agreements with University of Eastern Piedmont and Spanish Research Council
07:40am, Tuesday, 07'th Jun 2022
Skye Bioscience inc (OTCQB:SKYE) said it has signed new research agreements with the University of Eastern Piedmont (UPO) in Italy and the Spanish Research Council (CSIC), focusing on developing an e
Skye Bioscience to Present at LD Micro Invitational
08:00am, Monday, 06'th Jun 2022
San Diego, California--(Newsfile Corp. - June 6, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivativ
Skye Bioscience signs agreement to merge with Emerald Health Therapeutics
09:53am, Thursday, 12'th May 2022
Skye Bioscience Inc (OTCQB:SKYE) and Emerald Health Therapeutics Inc said they have entered into a definitive agreement that will see Skye acquiring Emerald in a share-for-share transaction. Under th
Skye Bioscience says study shows enhanced reduction in intraocular pressure with its SBI-100 formulation for glaucoma
08:43am, Thursday, 05'th May 2022
Skye Bioscience inc (OTCQB:SKYE) announced that the peer-reviewed journal International Journal of Pharmaceutics has published preclinical data demonstrating stronger and longer-lasting reduction of i
Skye Bioscience hires CMAX to run its phase 1 study of lead candidate SBI-100 OE for glaucoma
08:12am, Thursday, 28'th Apr 2022
Skye Bioscience inc (OTCQB:SKYE) said it has hired experienced Australian clinical trial operator CMAX to run its phase 1 study of lead candidate SBI-100 OE to treat glaucoma in Adelaide with final da
Skye Bioscience partners with Novatech Heath Holdings for Phase I trial of glaucoma drug candidate
09:34am, Thursday, 03'rd Mar 2022
Skye Bioscience inc (OTCQB:SKYE) announced that it has entered into an agreement with Novotech Health Holdings, a leading full-service contract research organization (CRO) in Asia-Pacific, for the upc
Skye Bioscience reports positive results for SB-100 in GLP toxicology study; Phase I clinical trial expected in 2Q 2022
09:19am, Wednesday, 16'th Feb 2022
Skye Bioscience inc (OTCQB:SKYE) announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ophthalmic nanoemulsion in support of the company's planne
Skye Bioscience CEO Punit Dhillon says company 'fast approaching' first-in-human Phase I study in 2022 for SBI-100
12:33pm, Monday, 10'th Jan 2022
Skye Bioscience inc (OTCQB:SKYE) issued a letter to its shareholders written by CEO Punit Dhillon, highlighting the achievements of 2021 and providing the business outlook for 2022. “2021 represente
Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program
01:35pm, Tuesday, 12'th Oct 2021
Exclusive sponsored research agreement with endocannabinoid research pioneers Exclusive sponsored research agreement with endocannabinoid research pioneers
Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer
08:30am, Tuesday, 05'th Oct 2021
SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases
Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering
04:30pm, Wednesday, 29'th Sep 2021
SAN DIEGO, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-deriv
